Arrival at last of Clinical Success

Today we received news of a landmark success in AIMT's clinical trial of "Palisade" a treatment for severe peanut allergies. markets.businessinsider.com/news/stocks/aimmune-palisade-trial-of-ar101-published-in-new-england-journal-of-medicine-1027736686
I am expecting a substantial surge in price in pre market and the first hour of trading tomorrow so either get your order in fast or wait for it to come back down a bit once the daytraders have scoured their winnings. The previous high is around $40 but is a 33% gain a realistic expectation for a daytrade? Probably not, but it is a very attainable goal for medium to long term positions which is how I intend to approach this trade. The company is in good financial health and there is a high probability AIMT will be granted fast track status for FDA approval once they formally submit their application next month. There is currently no treatments on the market today for increasing tolerance of peanut exposure to those who are inflicted with severe allergies so there is no product or company to compare the future profitability of AIMT and palaside but its safe to say this stock is going UP!